Kahn Brothers Group Inc. Invests $8.30 Million in GSK PLC Sponsored ADR $GSK

Kahn Brothers Group Inc. purchased a new stake in GSK PLC Sponsored ADR (NYSE:GSK) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 158,438 shares of the pharmaceutical company’s stock, valued at approximately $8,305,000. GSK makes up 0.0% of Kahn Brothers Group Inc.’s investment portfolio, making the stock its 28th biggest holding.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GSK. Brighton Jones LLC bought a new stake in shares of GSK during the fourth quarter valued at about $528,000. Dorsey Wright & Associates purchased a new position in GSK during the first quarter valued at approximately $2,522,000. PFA Pension Forsikringsaktieselskab bought a new stake in GSK during the 4th quarter worth approximately $6,385,000. Fisher Asset Management LLC boosted its holdings in GSK by 3.0% in the 4th quarter. Fisher Asset Management LLC now owns 33,195,985 shares of the pharmaceutical company’s stock valued at $1,627,931,000 after purchasing an additional 968,370 shares during the period. Finally, Leuthold Group LLC purchased a new position in shares of GSK during the 4th quarter valued at $4,922,000. 15.74% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on GSK shares. Wall Street Zen cut shares of GSK from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of GSK in a research report on Thursday, July 30th. Royal Bank Of Canada restated an “outperform” rating on shares of GSK in a research note on Tuesday, June 9th. Citigroup assumed coverage on GSK in a report on Friday, July 24th. They issued a “neutral” rating on the stock. Finally, Jefferies Financial Group upgraded GSK to a “strong-buy” rating in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $53.00.

GSK Price Performance

Shares of NYSE:GSK opened at $50.27 on Friday. The company’s fifty day moving average price is $51.82 and its 200-day moving average price is $53.51. The firm has a market capitalization of $101.69 billion, a price-to-earnings ratio of 15.72, a PEG ratio of 2.97 and a beta of 0.36. GSK PLC Sponsored ADR has a one year low of $38.63 and a one year high of $61.69. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52.

GSK (NYSE:GSK) last posted its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The company had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.02 billion. During the same period in the previous year, the firm posted $0.47 EPS. The firm’s revenue was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, equities research analysts anticipate that GSK PLC Sponsored ADR will post 4.8 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Stockholders of record on Friday, August 14th will be given a dividend of $0.4515 per share. This is a boost from GSK’s previous quarterly dividend of $0.44. The ex-dividend date is Friday, August 14th. This represents a $1.81 annualized dividend and a dividend yield of 3.6%. GSK’s dividend payout ratio is currently 55.63%.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.